

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593 B2
APPLICATION NO. : 10/529116
DATED : December 9, 2008
INVENTOR(S) : Cuttitta et al.

Page 1 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

Page 1, Item (56) under Other Publications, "NH₂-terminal" should read
--NH₂-terminal--.

Page 1, Item (56) under Other Publications, "Gelatinases" should read
--Gelatinases--.

Page 2, Item (56) under Other Publications, "Adrenomedulling" should read
--Adrenomedullin--.

In column 2, lines 34-35, "for use in treating retinopathy" is a repeated phrase
that should be deleted.

In column 3, line 19, "p<0.001" should read --p<0.001.--.

In column 3, line 47, "0.01p>0.001" should read --0.01>p>0.001--.

In column 3, line 56, "angiogenesis" should read --angiogenesis.--.

In column 4, lines 35-41, "PGDF" should read --PDGF--.

In column 4, lines 42-43, "18 S RNA" should read --18 S RNA--.

In column 4, line 42, "prier" should read --primer--.

In column 6, line 2, "Ophthalmol." should read --Ophthalmol.--.

In column 7, line 39, "compliment" should read --complement--.

In column 7, line 51, "complimentary" should read --complementary--.

In column 7, line 56, "membrances" should read --membranes--.

In column 8, line 19, "arthritis considered" should read --arthritis is considered--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593 B2
APPLICATION NO. : 10/529116
DATED : December 9, 2008
INVENTOR(S) : Cuttitta et al.

Page 2 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 9, line 27, "tansyocardial" should read --transmyocardial--.

In column 22, line 19 (in Table 1), "Orignal" should read --Original--.

In column 22, line 48, "leucyl isoleucyl" should read --leucyl, isoleucyl--.

In column 22, line 52, "glutamnyl" should read --glutamyl--.

In column 24, line 7, "three dimensional" should read --three-dimensional--.

In column 24, line 21, "*Munson*" should read --Munson--.

In column 24, line 21, "Pharmacology Munson" should read --Pharmacology,
Munson--.

In column 25, line 1, "described GFP" should read --described for GFP--.

In column 25, line 3, "interest When" should read --interest. When--.

In column 25, line 9, "western blots" should read --Western blots--.

In column 25, lines 44-45, "a defined periods" should read --a defined period--.

In column 26, line 12, "characteization" should read --characterization--.

In column 27, line 2, "Marinastat" should read --Marimastat--.

In column 27, line 35, "sublingual oral" should read --sublingual, oral--.

In column 27, line 54, "mirocapsules" should read --microcapsules--.

In column 27, line 60, "intra-arterial intramuscular" should read --intra-arterial,
intramuscular--.

In column 30, line 9, "Non-queueous" should read --Non-aqueous--.

In column 30, line 60, "press" should read --Press--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593 B2
APPLICATION NO. : 10/529116
DATED : December 9, 2008
INVENTOR(S) : Cuttitta et al.

Page 3 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 30, line 64, "effect" should read --affect--.

In column 31, line 5, "1988);" should read --1988;--.

In column 31, line 6, "1989);" should read --1989;--.

In column 31, line 37, "trascutaneous" should read --transcutaneous--.

In column 32, line 3, "ad administered" should read --administered--.

In column 32, line 9, "admniistered" should read --administered--.

In column 33, lines 66-67, "peptido-encoding" should read --peptide-encoding--.

In column 34, line 49, "100µl mouse" should read --100µl per mouse--.

In column 34, line 53, "placed an eppendorf" should read --placed in an

Eppendorf--.

In column 35, line 46, "13 day-old" should read --13-day-old--.

In column 35, line 62, "DLVAA" should read --DIVAA--.

In column 35, line 63, "Am. J." should read --Am. J.--.

In column 35, line 64, "143 1-1439" should read --1431-1439--.

In column 36, line 16, "ATTC" should read --ATCC--.

In column 36, line 26, "molecular" should read --Molecular--.

In column 37, line 24, "reaction" should read --reaction.--.

In column 37, lines 42-45, "PGDF" should read --PDGF--.

In column 37, line 57, "19" should read --19)--.

In column 37, line 59, "18 5 RNA" should read --18 S RNA--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593 B2
APPLICATION NO. : 10/529116
DATED : December 9, 2008
INVENTOR(S) : Cuttitta et al.

Page 4 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 38, line 32, "Am. J." should read --Am. J.--.

In column 38, lines 45-46, "compared to and VEGF" should read --compared to AM and VEGF--.

In column 38, line 62, "20 19-2028" should read --2019-2028--.

In column 39, lines 21-23, "their effects on growth were compared (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C)." should read --their effects on growth (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C) were compared--.

In column 39, line 57, "undistinguishable" should read --indistinguishable--.

In column 40, line 43, "(12~20)" should read --(12-20)--.


In column 41, line 3, "inamunoassay" should read --immunoassay--.

In column 41, line 9, "Opthalmol." should read --Ophthalmol.--.

In column 42, line 16, "Opthalmol." should read --Ophthalmol.--.

Signed and Sealed this

Twenty-first Day of April, 2009



JOHN DOLL
Acting Director of the United States Patent and Trademark Office